Changes in tryptophan and phenylalanine in chronic HCV patients treated with direct acting antiviral (sofosbuvir)
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2522-8307
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Changes in tryptophan and phenylalanine in chronic HCV patients treated with direct acting antiviral (sofosbuvir) ; volume:42 ; number:1 ; day:9 ; month:11 ; year:2018 ; pages:1-7 ; date:12.2018
Bulletin of the National Research Centre / al- Markaz al-Qaumī li-'l-Buḥūṭ; 42, Heft 1 (9.11.2018), 1-7, 12.2018
- Urheber
-
Behiry, Eman G.
Mahmoud, Sara K.
Swelim, Mohamed A.
El-dougdoug, Khaled A.
A., Attia A.
Hussein, Ahmed M.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s42269-018-0023-4
- URN
-
urn:nbn:de:101:1-2018122800032852145710
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
2025-08-14T11:02:57+0200
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Behiry, Eman G.
- Mahmoud, Sara K.
- Swelim, Mohamed A.
- El-dougdoug, Khaled A.
- A., Attia A.
- Hussein, Ahmed M.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Tryptophan depletion results in tryptophan-to-phenylalanine substitutants
Author Correction: Tryptophan depletion results in tryptophan-to-phenylalanine substitutants
Knowledge-based repositioning of the anti-HCV direct antiviral agent Sofosbuvir as SARS-CoV-2 treatment
Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection
No tryptophan, tyrosine and phenylalanine abnormalities in children with attention-deficit/hyperactivity disorder
A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients
HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b
Early sofosbuvir-ledipasvir treatment for acute HCV infection induced severe immune thrombocytopenia – a case report
Safety and efficacy of directly acting antivirals (sofosbuvir and daclatasvir) in treatment of chronic HCV in HIV-HCV co-infected Egyptian patients
A systematic review of sofosbuvir/velpatasvir/voxilaprevir in HCV patients previously treated with direct-acting antivirals
Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection
Detection of a genetic footprint of the sofosbuvir resistance-associated substitution S282T after HCV treatment failure
Tryptophan depletion results in tryptophan-to-phenylalanine substitutants
Author Correction: Tryptophan depletion results in tryptophan-to-phenylalanine substitutants
Knowledge-based repositioning of the anti-HCV direct antiviral agent Sofosbuvir as SARS-CoV-2 treatment
Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection
No tryptophan, tyrosine and phenylalanine abnormalities in children with attention-deficit/hyperactivity disorder
A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients
HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b
Early sofosbuvir-ledipasvir treatment for acute HCV infection induced severe immune thrombocytopenia – a case report
Safety and efficacy of directly acting antivirals (sofosbuvir and daclatasvir) in treatment of chronic HCV in HIV-HCV co-infected Egyptian patients
A systematic review of sofosbuvir/velpatasvir/voxilaprevir in HCV patients previously treated with direct-acting antivirals
Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection
Detection of a genetic footprint of the sofosbuvir resistance-associated substitution S282T after HCV treatment failure
Tryptophan depletion results in tryptophan-to-phenylalanine substitutants
Author Correction: Tryptophan depletion results in tryptophan-to-phenylalanine substitutants
Knowledge-based repositioning of the anti-HCV direct antiviral agent Sofosbuvir as SARS-CoV-2 treatment
Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection
No tryptophan, tyrosine and phenylalanine abnormalities in children with attention-deficit/hyperactivity disorder
A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients
HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b
Early sofosbuvir-ledipasvir treatment for acute HCV infection induced severe immune thrombocytopenia – a case report
Safety and efficacy of directly acting antivirals (sofosbuvir and daclatasvir) in treatment of chronic HCV in HIV-HCV co-infected Egyptian patients
A systematic review of sofosbuvir/velpatasvir/voxilaprevir in HCV patients previously treated with direct-acting antivirals
Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection